Nisoldipine
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 388.41 |
Cas No. | 63675-72-9 |
Formula | C20H24N2O6 |
Solubility | insoluble in H2O; ≥10.62 mg/mL in EtOH; ≥11.55 mg/mL in DMSO |
Chemical Name | 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
SDF | Download SDF |
Canonical SMILES | CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
激酶实验 [1]: | |
电生理学结合实验 |
将表达电压依赖性L型Ca2+通道亚基的CHO细胞置于无血清培养液中,加入不同浓度的Nisoldipine。使用List EPC-7膜片钳放大器和pClamp软件。采用-100 mV或-50 mV的恒定电流刺激细胞时,于室温下记录Ca2+通道电流值。计算IC50值。 |
细胞实验 [2]: | |
细胞系 |
豚鼠心室肌细胞 |
制备方法 |
在DMSO中的溶解度大于11.6 mg/mL。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。 |
反应条件 |
10 ~ 100 μM;8 ~ 10分钟 |
实验结果 |
在豚鼠心室肌细胞中,Nisoldipine抑制快速激活延迟整流K+电流 (I(Kr) ),其IC50值为23 μM。Nisoldipine也抑制缓慢激活延迟整流K+电流 (I(Ks) ),其IC50值为40 μM。据估计,相对于延迟整流K+通道, Nisoldipine对L型Ca2+通道的选择性高约30倍。 |
动物实验 [3]: | |
动物模型 |
冠状动脉缺血再灌注犬模型 |
给药剂量 |
6.6 μg/kg/min;静脉注射 |
实验结果 |
与对照组相比,Nisoldipine治疗组显示出类似的血液动力学数值。然而,Nisoldipine组的坏死块和潜在坏死块显著较低。在冠状动脉缺血再灌注犬模型中,Nisoldipine降低梗死面积。 |
注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [2]. Missan S1, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF. Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70. [3]. Hammerman H, Moscovitz M, Hir J. Beneficial effect of nisoldipine in repeated coronary reperfusion. Coron Artery Dis. 1997 Feb;8(2):97-100. |
质量控制和MSDS
- 批次: